The results were stellar, considering the patients received, only, two doses of Leronlimab. The patient response was wonderful, while they had Leronlimab in their system. Their response tapered drastically, when they did not. Weird! We were, again, hobbled by the FDA (who did not act appropriately on behalf of the patients). How can you rate the efficacy, of a treatment, if you are not allowed to administer it properly? I will stop here, before my blood boils!